Register for free to
view the full innovation profile.
Increased energy expenditure with reduced appetite and food intake
About
Research has found that the molecule oxyntomodulin reduces appetite and increases metabolism. Human studies have found significant weight loss in obese volunteers above and beyond that seen with GLP-1 analogues alone. We have secured patents in major markets for the use of oxyntomodulin analogues in the treatment and prevention of obesity. This technology is now available for licensing to a development partner on a global or regional basis. Having completed several phase 1 studies this molecule is now ready for Phase 2 studies in a once a day formulation (subcutaneous injection). Alternatively the molecule could be re-formulated into a slow release formulation with a suitable partner. When contacting us, please quote internal reference number 2003.